WO2008120724A1 - Medicinal solid-dispersion preparation - Google Patents

Medicinal solid-dispersion preparation Download PDF

Info

Publication number
WO2008120724A1
WO2008120724A1 PCT/JP2008/056105 JP2008056105W WO2008120724A1 WO 2008120724 A1 WO2008120724 A1 WO 2008120724A1 JP 2008056105 W JP2008056105 W JP 2008056105W WO 2008120724 A1 WO2008120724 A1 WO 2008120724A1
Authority
WO
WIPO (PCT)
Prior art keywords
dispersion preparation
medicinal solid
cilnidipine
medicinal
solid
Prior art date
Application number
PCT/JP2008/056105
Other languages
French (fr)
Japanese (ja)
Inventor
Hiroyuki Higuchi
Ichiro Hara
Original Assignee
Ajinomoto Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co., Inc. filed Critical Ajinomoto Co., Inc.
Priority to JP2009507521A priority Critical patent/JP5828616B2/en
Publication of WO2008120724A1 publication Critical patent/WO2008120724A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

A medicinal solid-dispersion preparation containing a cilnidipine compound. It has high water solubility and hence has high solubility in the digestive tract. It has a high extent of bioavailability. The medicinal solid-dispersion preparation comprises: cilnidipine or a pharmaceutically acceptable salt thereof; and a specific water-soluble polymer (i.e., a specific cellulose, derivative thereof, synthetic polymer, natural polymer, or saccharide).
PCT/JP2008/056105 2007-03-30 2008-03-28 Medicinal solid-dispersion preparation WO2008120724A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009507521A JP5828616B2 (en) 2007-03-30 2008-03-28 Solid dispersion formulation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007-094659 2007-03-30
JP2007094659 2007-03-30
JP2007209213 2007-08-10
JP2007-209213 2007-08-10

Publications (1)

Publication Number Publication Date
WO2008120724A1 true WO2008120724A1 (en) 2008-10-09

Family

ID=39808304

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/056105 WO2008120724A1 (en) 2007-03-30 2008-03-28 Medicinal solid-dispersion preparation

Country Status (3)

Country Link
JP (2) JP5828616B2 (en)
KR (1) KR20100016093A (en)
WO (1) WO2008120724A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5790965B2 (en) * 2012-10-12 2015-10-07 味の素株式会社 Method for producing pharmaceutical preparation containing calcium antagonist / angiotensin II receptor antagonist
US10231929B2 (en) 2014-03-18 2019-03-19 Takeda Pharmaceutical Company Limited Solid dispersion

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04360833A (en) * 1991-06-05 1992-12-14 Fujirebio Inc Pharmaceutical containing 1,4-dihydropyridine derivative
WO1997006781A1 (en) * 1995-08-11 1997-02-27 Nissan Chemical Industries, Ltd. Methods for making hardly soluble medicine amorphous
JP2004534811A (en) * 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク Pharmaceutical composition comprising a polymer and drug assembly
WO2007029660A1 (en) * 2005-09-06 2007-03-15 Astellas Pharma Inc. Microparticle of hardly-soluble substance having enteric base material adsorbed on the surface of the substance
JP2007308487A (en) * 2006-04-19 2007-11-29 Ajinomoto Co Inc Method for film-coating solid-dispersed material

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH054919A (en) * 1990-07-25 1993-01-14 Sankyo Co Ltd Solid dispersion of thiazolidine derivative
JPH05310571A (en) * 1991-07-01 1993-11-22 Ishihara Sangyo Kaisha Ltd Anti-cancer medicine composition of amorphous benzoylurea-based compound
JPH07324086A (en) * 1994-05-31 1995-12-12 Sankyo Co Ltd Solid dispersion of thiazolidine derivative or pharmaceutical preparation of solid dispersion
WO1996019239A1 (en) * 1994-12-21 1996-06-27 Yamanouchi Pharmaceutical Co., Ltd. Solid composition with improved solubility and absorbability

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04360833A (en) * 1991-06-05 1992-12-14 Fujirebio Inc Pharmaceutical containing 1,4-dihydropyridine derivative
WO1997006781A1 (en) * 1995-08-11 1997-02-27 Nissan Chemical Industries, Ltd. Methods for making hardly soluble medicine amorphous
JP2004534811A (en) * 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク Pharmaceutical composition comprising a polymer and drug assembly
WO2007029660A1 (en) * 2005-09-06 2007-03-15 Astellas Pharma Inc. Microparticle of hardly-soluble substance having enteric base material adsorbed on the surface of the substance
JP2007308487A (en) * 2006-04-19 2007-11-29 Ajinomoto Co Inc Method for film-coating solid-dispersed material

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SUZUKI H. ET AL.: "Influence of water-soluble polymers on the dissolution of nifedipine solid dispersions with combined carriers", CHEM. PHARM. BULL. (TOKYO), vol. 46, no. 3, 1998, pages 482 - 487, XP000748996 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5790965B2 (en) * 2012-10-12 2015-10-07 味の素株式会社 Method for producing pharmaceutical preparation containing calcium antagonist / angiotensin II receptor antagonist
US10231929B2 (en) 2014-03-18 2019-03-19 Takeda Pharmaceutical Company Limited Solid dispersion

Also Published As

Publication number Publication date
JP6072705B2 (en) 2017-02-01
KR20100016093A (en) 2010-02-12
JPWO2008120724A1 (en) 2010-07-15
JP5828616B2 (en) 2015-12-09
JP2014058584A (en) 2014-04-03

Similar Documents

Publication Publication Date Title
WO2006119498A3 (en) Pharmaceutical compositions with synchronized solubilizer release
WO2010062688A3 (en) Dosage form for insertion into the mouth
IL196979A (en) Pharmaceutical extended release system comprising flibanserin and ph dependent polymers, a process for preparing it and a capsule comprising it
WO2008006795A3 (en) Indole compounds
WO2009066315A3 (en) Sustained release compositions of trimetazidine and process for preparation thereof
IL222792A0 (en) Method of coupling an oligosaccharide to a protein, oligosaccharide-protein conjugates, uses thereof and pharmaceutical compositions comprising the same
WO2007144169A3 (en) Entacapone-derivatives
TW200700062A (en) Pharmaceutical compositions
IL195931A (en) Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and methods for its production
WO2011037976A3 (en) Pramipexole pharmaceutical formulations
WO2009064681A3 (en) Liquid compositions comprising valsartan
EP1968606A4 (en) Preparation of pharmaceutical salts of 3-o-(3',3'-dimethylsuccinyl) betulinic acid
WO2007083190A3 (en) Water insoluble helichrysum extract, process for preparing the same and uses thereof
WO2010046932A3 (en) Extended release pharmaceutical composition of minocycline and process thereof
EP2196463A4 (en) Preparation of 5,6-dimethylxanthone-4-acetic acid, the derivatives prepared and pharmaceutical formulations thereof
WO2008135828A3 (en) Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2006034147A3 (en) Compositions and methods for the preparation and administration of poorly water soluble drugs
WO2007110753A3 (en) Extended release dosage forms of metoprolol
WO2007144699A3 (en) Process for the preparation of alfuzosin
WO2008120724A1 (en) Medicinal solid-dispersion preparation
ZA200902414B (en) Indole derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2007086911A3 (en) Stable nanoparticle formulations
EP2494955A3 (en) Stable liquid pharmaceutical composition based on trazodone
EP2130834A4 (en) Novel sulfonated sugar derivative, and use thereof for medicinal agent
WO2007016315A3 (en) Extended release venlafaxine compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08739223

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009507521

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20097022769

Country of ref document: KR

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 08739223

Country of ref document: EP

Kind code of ref document: A1